<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160198</url>
  </required_header>
  <id_info>
    <org_study_id>114204</org_study_id>
    <nct_id>NCT01160198</nct_id>
  </id_info>
  <brief_title>A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.</brief_title>
  <official_title>A Multicentre, Randomized, Laboratory-blinded, Parallel-group Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Iron deficiency anaemia (Haemoglobin, Hb &lt; 12gm/dl) is one of India's major public health
      problems particularly in women. Effective control of iron deficiency anaemia decreases the
      incidence of fatigue, bodyache, headache, lack of concentration and menstrual complications.
      Iron bisglycine chelate has been used successfully to treat iron deficiency anaemia and is
      also a well tolerated therapy. Use of ferrous bisglycinate chelate one tablet daily as a
      nutritional supplement is well established in India. For treatment of iron deficiency
      anaemia, some women may need 1 tablet/day, while some may need 2 tablets/day. In India,
      ferrous ascorbate, 1 tablet daily is a widely accepted form of treatment for iron deficiency
      anaemia. The primary purpose of this study is to demonstrate the efficacy and tolerability
      profile of ferrous bisglycinate chelate to support the registration of this product as a
      'drug' in India. Comparative data between ferrous bisglycinate chelate and ferrous ascorbate
      will also augment our existing knowledge, which will further support appropriate use of
      ferrous bisglycinate chelate for the treatment of iron deficiency anaemia. Study design and
      patient population: This will be a multicentre, randomized, laboratory-blinded, parallel-
      group study. It is projected that the study will randomize 270 women (90 subjects in each
      treatment arm) with iron deficiency anaemia (Hb 6-9 gm/dl + serum Ferritin &lt;15 μg/l) to
      either ferrous bisglycinate chelate 1 or 2 tablets/day, or ferrous ascorbate 1 tablet/day for
      8 weeks. At fortnightly visits, blood will be collected for Hb (to evaluate efficacy),
      adverse events will be documented (to evaluate tolerability), the investigational drugs will
      be dispensed and reasons for non compliance will be recorded. Study endpoints: The primary
      endpoint is defined as the rise of Hb from baseline after 8 weeks of treatment in each
      ferrous bisglycinate chelate group (1 tablet/day and 2 tablets/day). The secondary endpoints
      include the difference in the average change in Hb, difference in the rate of rise of Hb,
      difference in the proportion of patients who achieve a target Hb ≥12gm/dl and difference in
      the % incidence of gastrointestinal side effects during 8 week therapy with 2 dosing regimens
      of ferrous bisglycinate chelate (1 tablet/day and 2 tablets/day) and ferrous ascorbate 1
      tablet/day.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale Iron deficiency is the most common form of malnutrition globally. In India, nearly
      70% of women are estimated to be iron deficient. Iron deficiency anemia (IDA, Hb &lt;12gm/dl) is
      a very late manifestation of iron deficiency. IDA is a consequence of decreased iron intake,
      increased iron loss from the body or increased iron requirements Blood loss during
      menstruation can predispose women to have poor iron stores and the presence of excess
      menstrual bleeding can contribute to the development of IDA in women. Patients with IDA
      usually present with fatigue, headache, bodyache, paraesthesia and lack of concentration. IDA
      can cause menorrhagia, which in turn can aggravate IDA. With severe anemia, there may be
      amenorrhoea as well.

      Iron deficiency anaemia is often treated with iron tablets such as ferrous sulphate, ferrous
      fumarate and ferrous gluconate. It usually takes about 6-10 weeks for Hb to return to normal
      after initiation of oral iron therapy. Although efficacious from a haematological point of
      view, most of these therapies are associated with limiting gastrointestinal side effects
      (e.g. nausea, vomiting, constipation, diarrhoea and abdominal pain), which eventually reduce
      patient compliance.

      Among the recent alternatives, iron bisglycine chelate has been used successfully to treat
      iron deficiency anaemia and is also a well tolerated therapy.

      Use of ferrous bisglycinate chelate (each tablet contains 60mg of elemental iron as ferrous
      bisglycinate chelate, 1 mg folic acid, 5 mcg cyanocobalamin and 15 mg zinc bis-glycinate), 1
      tablet daily is well established as a nutritional supplement in India. However, for treatment
      of iron deficiency anaemia, some women may need 1 tablet/day, while some may need 2 tablets
      /day.

      In India, ferrous ascorbate tablets (each tablet contains 100 mg elemental iron as ferrous
      ascorbate, with 1 mg folic acid) in the recommended dose of 1 tablet daily are a widely
      accepted form of treatment for iron deficiency anaemia.

      The primary purpose of this study is to demonstrate the efficacy and tolerability profile of
      ferrous bisglycinate chelate to support the registration of this product as a 'drug' in
      India. Comparative data between ferrous bisglycinate chelate and ferrous ascorbate will also
      augment our existing knowledge, which will further support the use of ferrous bisglycinate
      chelate for the treatment of iron deficiency anaemia.

      Objective(s)

      Primary:

      To estimate the mean rise in haemoglobin level in patients with iron deficiency anaemia after
      8 weeks of treatment (vs. baseline) with ferrous bisglycinate chelate (1 tablet and 2 tablets
      daily).

      Secondary:

        1. To compare the mean rise in haemoglobin in patients with iron deficiency anaemia after 8
           weeks treatment with ferrous bisglycinate chelate, 1 tablet and 2 tablets daily vs.
           ferrous ascorbate 1 tablet daily.

        2. To compare the average rate of rise of haemoglobin during 8 weeks of treatment with
           ferrous bisglycinate chelate 1 tablet daily, ferrous bisglycinate chelate 2 tablets
           daily and ferrous ascorbate 1 tablet daily.

        3. To compare the proportion of patients who achieve a target Hb ≥ 12gm/dl after 8 weeks of
           treatment with ferrous bisglycinate chelate 1 tablet daily, ferrous bisglycinate chelate
           2 tablets daily and ferrous ascorbate 1 tablet daily.

        4. To compare the % incidence of gastrointestinal side effects during 8 weeks treatment
           with ferrous bisglycinate chelate 1 tablet daily, ferrous bisglycinate chelate 2 tablets
           daily and ferrous ascorbate 1 tablet daily.

      Study Design This will be a multicentre, randomized, laboratory-blinded, parallel-group
      study. It is projected that the study will randomize 270 women (90 subjects in each treatment
      arm) with iron deficiency anaemia (Hb 6-9 gm/dl + serum Ferritin &lt;15 μg/l) to either ferrous
      bisglycinate chelate 1 tablet/day, ferrous bisglycinate chelate 2 tablets/day or ferrous
      ascorbate 1 tablet/day for 8 weeks. At fortnightly visits, blood will be collected for Hb (to
      evaluate efficacy), adverse events will be documented (to evaluate tolerability), the
      investigational drugs will be dispensed and reasons for non compliance will be recorded.

      The total study duration consists of an 8-week treatment period and will involve 6 clinic
      visits.

      Study Endpoints/Assessments Primary Endpoint(s) Rise of haemoglobin from baseline to 8 weeks
      in each ferrous bisglycinate chelate group (1 tablet daily and 2 tablets daily).

      Secondary Endpoint(s)

        1. The difference in the average change in Hb from baseline to 8 weeks with ferrous
           bisglycinate chelate 1 and 2 tablets daily, and ferrous ascorbate 1 tablet daily.

        2. The difference in the average rate of rise of Hb during 8 weeks of treatment with
           ferrous bisglycinate chelate 1 tablet daily, ferrous bisglycinate chelate 2 tablets
           daily, and ferrous ascorbate 1 tablet daily.

        3. The difference in proportion of patients who achieve a target Hb ≥12gm/dl after 8 weeks
           of treatment with ferrous bisglycinate chelate 1 tablet daily, ferrous bisglycinate
           chelate 2 tablets daily, and ferrous ascorbate 1 tablet daily.

        4. The difference in % incidence of gastrointestinal side effects during 8 weeks treatment
           with ferrous bisglycinate chelate 1 tablet daily, ferrous bisglycinate chelate 2 tablets
           daily and ferrous ascorbate 1 tablet daily.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 13, 2010</start_date>
  <completion_date type="Actual">February 18, 2011</completion_date>
  <primary_completion_date type="Actual">February 18, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin (Hb) After 8 Weeks of Treatment in Each Ferrous Bisglycinate Chelate Group (1 Tablet Daily and 2 Tablets Daily)</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>At fortnightly visits, blood was collected for Hb. Baseline (Visit 0) was not more than 5 days from Week 1 or randomization. Change from Baseline was calculated by subtracting Baseline values from post-Baseline values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Hb From Baseline to 8 Weeks</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>At fortnightly visits, blood was collected for Hb. Baseline (Visit 0) was not more than 5 days from Week 1 or randomization. Change from Baseline was calculated by subtracting Baseline values from post-Baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved a Target Hb More Than or Equal to 12 gm/dL After 8 Weeks of Treatment</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>At fortnightly visits, blood was collected for Hb. Number of participants who achieved a target Hb of more than or equal to 12 gm/dL is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Hb During 8 Weeks Therapy</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>At fortnightly visits, blood was collected for Hb. Mean change in Hb at Week 2, Week 4, Week 6 and Week 8 are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Percentage of Participants With Gastrointestinal Side Effects During 8 Weeks Treatment With Ferrous Bisglycinate Chelate and Ferrous Ascorbate</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>The comparison in percentage of participants with gastrointestinal side effects during 8 week treatment period is reported. Gastrointestinal side effects during 8 weeks treatment included abdominal discomfort, gastritis, nausea, dyspepsia, change in bowel habit, constipation, faeces discolored, diarrhea and flatulence.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">271</enrollment>
  <condition>Haematopoiesis</condition>
  <arm_group>
    <arm_group_label>ferrous bisglycinate chelate 1 OD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ferrous bisglycinate chelate 1 tablet daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ferrous ascorbate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ferrous ascorbate, 1 tablet daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ferrous bisglycinate chelate 2 OD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ferrous bisglycinate chelate 2 tablets daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ferrous ascorbate</intervention_name>
    <description>100 mg elemental iron</description>
    <arm_group_label>ferrous ascorbate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ferrous bisglycinate chelate 1 OD</intervention_name>
    <description>60 mg elemental iron</description>
    <arm_group_label>ferrous bisglycinate chelate 1 OD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ferrous bisglycinate chelate 2 OD</intervention_name>
    <description>120 mg elemental iron</description>
    <arm_group_label>ferrous bisglycinate chelate 2 OD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Subjects eligible for enrolment to the study must meet all of the following criteria:

          1. Signed and dated written informed consent is obtained prior to participation.

          2. Female outpatients between 18 to 55 years of age and using effective method of
             contraception if sexually active.

          3. Non use of any iron supplement for 3 months prior to enrolment to the study.

          4. Presence of iron deficiency anaemia: low haemoglobin (Hb 6-9 gm/dl) + low serum
             ferritin (&lt;15 μg/l).

          5. No occult blood in stool.

          6. Able to comply with the requirements of the protocol.

          7. Subjects should have a valid telephone contact.

        Exclusion Criteria

        Subjects meeting any of the following criteria must not be enrolled to the study:

          1. Pregnancy (confirmed by urine dipstick method)

          2. Desire to conceive within the next 3 months including patients who are receiving
             treatment to facilitate conception.

          3. Lactating women.

          4. Medical history of current hematological disorders other than iron deficiency anaemia
             (e.g. aplastic anaemia, megaloblastic anaemia, sideroblastic anaemia, pernicious
             anaemia, thalassemia, sickle cell anaemia, etc.).

          5. Medical history of thyroid dysfunction.

          6. Medical history of chronic renal disease.

          7. Medical history of malabsorption syndrome, haemochromatosis and haemosiderosis,
             hypochlorhydria, achlorhydria, gastrectomy, gastrojejunostomy.

          8. Inability to withhold prohibited medication.

          9. Obvious internal or external bleeding as documented by medical history and/or
             examination if considered clinically significant in the opinion of the investigator.

         10. Clinically significant abnormality in laboratory reports and/or ECG.

         11. Medical history of hepatitis B, hepatitis C and/or exposure to HIV.

         12. Serious, uncontrolled disease (other than thyroid dysfunction and chronic renal
             disease) including serious psychological disorders likely to interfere with the study
             and/or likely to cause death within the study period.

         13. Participation in another clinical trial in the last 8 weeks before entry to Visit 0.

         14. Evidence of alcohol or drug abuse, that may, in the opinion of the investigator
             interfere with study compliance or prevent understanding of the objectives,
             investigational procedures or possible consequences of the study.

         15. Known or suspected hypersensitivity to iron or any of the components of ferrous
             bisglycinate chelate or ferrous ascorbate tablets.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bhojipura, Bareilly</city>
        <zip>243202</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lucknow</city>
        <zip>226003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lucknow</city>
        <zip>226017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nagpur</city>
        <zip>440022</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pune</city>
        <zip>411 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Surat</city>
        <zip>395002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thane,Mumbai</city>
        <zip>400605</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2010</study_first_submitted>
  <study_first_submitted_qc>July 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <results_first_submitted>April 28, 2017</results_first_submitted>
  <results_first_submitted_qc>September 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2018</results_first_posted>
  <last_update_submitted>September 11, 2017</last_update_submitted>
  <last_update_submitted_qc>September 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chelating Agents</mesh_term>
    <mesh_term>Glycine</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 6 centers in India from 12-October-2010 to 17-February-2011. OROFER XT™ (ferrous ascorbate, 100 milligram [mg]) is a registered product of Emcure Pharmaceuticals Ltd., Pune and Ferronine™ (ferrous bisglycinate chelate, 60 mg) is registered product of GlaxoSmithKline.</recruitment_details>
      <pre_assignment_details>A total of 317 participants with iron deficiency anaemia were screened for this study; of these, 270 participants were randomized. Intent-to-Treat (ITT) population: all randomized participants who received at least one dose of study medication (n=270). Before randomization, all participants were dewormed with a single tablet of 400 mg albendazole.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ferrous Bisglycinate Chelate 60 mg 1 Once-daily</title>
          <description>Participants received ferrous bisglycinate chelate, 1 tablet of 60 mg, once-daily after dinner, via oral route for 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Ferrous Bisglycinate Chelate 60 mg 1 Twice-daily</title>
          <description>Participants received ferrous bisglycinate chelate, 1 tablet each of 60 mg, twice-daily after breakfast and dinner, via oral route for 8 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Ferrous Ascorbate 100 mg 1 Once-daily</title>
          <description>Participants received ferrous ascorbate, 1 tablet of 100 mg once-daily after dinner, via oral route for 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="91"/>
                <participants group_id="P3" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="88"/>
                <participants group_id="P3" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant lost drug; withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ferrous Bisglycinate Chelate 60 mg 1 Once-daily</title>
          <description>Participants received ferrous bisglycinate chelate, 1 tablet of 60 mg, once-daily after dinner, via oral route for 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Ferrous Bisglycinate Chelate 60 mg 1 Twice-daily</title>
          <description>Participants received ferrous bisglycinate chelate, 1 tablet each of 60 mg, twice-daily after breakfast and dinner, via oral route for 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Ferrous Ascorbate 100 mg 1 Once-daily</title>
          <description>Participants received ferrous ascorbate, 1 tablet of 100 mg once-daily after dinner, via oral route for 8 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="89"/>
            <count group_id="B2" value="91"/>
            <count group_id="B3" value="90"/>
            <count group_id="B4" value="270"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="270"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="270"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hemoglobin (Hb) After 8 Weeks of Treatment in Each Ferrous Bisglycinate Chelate Group (1 Tablet Daily and 2 Tablets Daily)</title>
        <description>At fortnightly visits, blood was collected for Hb. Baseline (Visit 0) was not more than 5 days from Week 1 or randomization. Change from Baseline was calculated by subtracting Baseline values from post-Baseline values.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Per protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferrous Bisglycinate Chelate 60 mg 1 Once-daily</title>
            <description>Participants received ferrous bisglycinate chelate, 1 tablet of 60 mg, once-daily after dinner, via oral route for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ferrous Bisglycinate Chelate 60 mg 1 Twice-daily</title>
            <description>Participants received ferrous bisglycinate chelate, 1 tablet each of 60 mg, twice-daily after breakfast and dinner, via oral route for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin (Hb) After 8 Weeks of Treatment in Each Ferrous Bisglycinate Chelate Group (1 Tablet Daily and 2 Tablets Daily)</title>
          <description>At fortnightly visits, blood was collected for Hb. Baseline (Visit 0) was not more than 5 days from Week 1 or randomization. Change from Baseline was calculated by subtracting Baseline values from post-Baseline values.</description>
          <population>Per protocol (PP) population.</population>
          <units>Gram per deciliter (gm/dL)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="2.12" upper_limit="3.03"/>
                    <measurement group_id="O2" value="2.8" lower_limit="2.36" upper_limit="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Baseline Hb vs. Hb at Week 8 for Ferrous bisglycinate chelate 60 mg 1 once-daily</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline Hb vs. Hb at Week 8 for Ferrous bisglycinate chelate 60 mg 1 twice-daily</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Hb From Baseline to 8 Weeks</title>
        <description>At fortnightly visits, blood was collected for Hb. Baseline (Visit 0) was not more than 5 days from Week 1 or randomization. Change from Baseline was calculated by subtracting Baseline values from post-Baseline values.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>PP population. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferrous Bisglycinate Chelate 60 mg 1 Once-daily</title>
            <description>Participants received ferrous bisglycinate chelate, 1 tablet of 60 mg, once-daily after dinner, via oral route for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ferrous Bisglycinate Chelate 60 mg 1 Twice-daily</title>
            <description>Participants received ferrous bisglycinate chelate, 1 tablet each of 60 mg, twice-daily after breakfast and dinner, via oral route for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ferrous Ascorbate 100 mg 1 Once-daily</title>
            <description>Participants received ferrous ascorbate, 1 tablet of 100 mg once-daily after dinner, via oral route for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Hb From Baseline to 8 Weeks</title>
          <description>At fortnightly visits, blood was collected for Hb. Baseline (Visit 0) was not more than 5 days from Week 1 or randomization. Change from Baseline was calculated by subtracting Baseline values from post-Baseline values.</description>
          <population>PP population. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>gm/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="2.12" upper_limit="3.03"/>
                    <measurement group_id="O2" value="2.8" lower_limit="2.36" upper_limit="3.31"/>
                    <measurement group_id="O3" value="2.6" lower_limit="2.19" upper_limit="3.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved a Target Hb More Than or Equal to 12 gm/dL After 8 Weeks of Treatment</title>
        <description>At fortnightly visits, blood was collected for Hb. Number of participants who achieved a target Hb of more than or equal to 12 gm/dL is presented.</description>
        <time_frame>Up to Week 8</time_frame>
        <population>PP population. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferrous Bisglycinate Chelate 60 mg 1 Once-daily</title>
            <description>Participants received ferrous bisglycinate chelate, 1 tablet of 60 mg, once-daily after dinner, via oral route for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ferrous Bisglycinate Chelate 60 mg 1 Twice-daily</title>
            <description>Participants received ferrous bisglycinate chelate, 1 tablet each of 60 mg, twice-daily after breakfast and dinner, via oral route for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ferrous Ascorbate 100 mg 1 Once-daily</title>
            <description>Participants received ferrous ascorbate, 1 tablet of 100 mg once-daily after dinner, via oral route for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved a Target Hb More Than or Equal to 12 gm/dL After 8 Weeks of Treatment</title>
          <description>At fortnightly visits, blood was collected for Hb. Number of participants who achieved a target Hb of more than or equal to 12 gm/dL is presented.</description>
          <population>PP population. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2"/>
                    <measurement group_id="O2" value="36.1"/>
                    <measurement group_id="O3" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ferrous bisglycinate chelate 60 mg 1 once-daily vs. Ferrous bisglycinate chelate 60 mg 1 twice-daily</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.788</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ferrous bisglycinate chelate 60 mg 1 once-daily vs. Ferrous ascorbate 100mg 1 once-daily</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.911</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ferrous bisglycinate chelate 60 mg 1 twice-daily vs. Ferrous ascorbate 100mg 1 once-daily</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.700</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Hb During 8 Weeks Therapy</title>
        <description>At fortnightly visits, blood was collected for Hb. Mean change in Hb at Week 2, Week 4, Week 6 and Week 8 are presented.</description>
        <time_frame>Up to Week 8</time_frame>
        <population>PP population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferrous Bisglycinate Chelate 60 mg 1 Once-daily</title>
            <description>Participants received ferrous bisglycinate chelate, 1 tablet of 60 mg, once-daily after dinner, via oral route for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ferrous Bisglycinate Chelate 60 mg 1 Twice-daily</title>
            <description>Participants received ferrous bisglycinate chelate, 1 tablet each of 60 mg, twice-daily after breakfast and dinner, via oral route for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ferrous Ascorbate 100 mg 1 Once-daily</title>
            <description>Participants received ferrous ascorbate, 1 tablet of 100 mg once-daily after dinner, via oral route for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Hb During 8 Weeks Therapy</title>
          <description>At fortnightly visits, blood was collected for Hb. Mean change in Hb at Week 2, Week 4, Week 6 and Week 8 are presented.</description>
          <population>PP population. Only those participants available at the specified time points were analyzed.</population>
          <units>gm/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.46" upper_limit="0.69"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.50" upper_limit="0.78"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.57" upper_limit="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.98" upper_limit="1.45"/>
                    <measurement group_id="O2" value="1.3" lower_limit="1.07" upper_limit="1.61"/>
                    <measurement group_id="O3" value="1.4" lower_limit="1.10" upper_limit="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.46" upper_limit="2.15"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1.58" upper_limit="2.32"/>
                    <measurement group_id="O3" value="1.9" lower_limit="1.56" upper_limit="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="2.12" upper_limit="3.03"/>
                    <measurement group_id="O2" value="2.8" lower_limit="2.36" upper_limit="3.31"/>
                    <measurement group_id="O3" value="2.6" lower_limit="2.19" upper_limit="3.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ferrous bisglycinate chelate 60 mg 1 once-daily vs. Ferrous bisglycinate chelate 60 mg 1 twice-daily at Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Repeated Measure ANOVA model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.29</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ferrous bisglycinate chelate 60 mg 1 once-daily vs. Ferrous bisglycinate chelate 60 mg 1 twice-daily at Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Repeated Measure ANOVA model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.57</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ferrous bisglycinate chelate 60 mg 1 once-daily vs. Ferrous bisglycinate chelate 60 mg 1 twice-daily at Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Repeated Measure ANOVA model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.75</ci_lower_limit>
            <ci_upper_limit>0.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ferrous bisglycinate chelate 60 mg 1 once-daily vs. Ferrous bisglycinate chelate 60 mg 1 twice-daily at Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Repeated Measure ANOVA model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.05</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ferrous bisglycinate chelate 60 mg 1 once-daily vs. Ferrous ascorbate 100mg 1 once-daily at Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.490</p_value>
            <method>Repeated Measure ANOVA model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ferrous bisglycinate chelate 60 mg 1 once-daily vs. Ferrous ascorbate 100 mg 1 once-daily at Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Repeated Measure ANOVA model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.58</ci_lower_limit>
            <ci_upper_limit>0.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ferrous bisglycinate chelate 60 mg 1 once-daily vs. Ferrous ascorbate 100 mg 1 once-daily at Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Repeated Measure ANOVA model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.68</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ferrous bisglycinate chelate 60 mg 1 once-daily vs. Ferrous ascorbate 100 mg 1 once-daily at Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Repeated Measure ANOVA model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ferrous bisglycinate chelate 60 mg 1 twice-daily vs. Ferrous ascorbate 100mg 1 once-daily at Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Repeated Measure ANOVA model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.29</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ferrous bisglycinate chelate 60 mg 1 twice-daily vs. Ferrous ascorbate 100 mg 1 once-daily at Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Repeated Measure ANOVA model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ferrous bisglycinate chelate 60 mg 1 twice-daily vs. Ferrous ascorbate 100 mg 1 once-daily at Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Repeated Measure ANOVA model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ferrous bisglycinate chelate 60 mg 1 twice-daily vs. Ferrous ascorbate 100 mg 1 once-daily at Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Repeated Measure ANOVA model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.58</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Percentage of Participants With Gastrointestinal Side Effects During 8 Weeks Treatment With Ferrous Bisglycinate Chelate and Ferrous Ascorbate</title>
        <description>The comparison in percentage of participants with gastrointestinal side effects during 8 week treatment period is reported. Gastrointestinal side effects during 8 weeks treatment included abdominal discomfort, gastritis, nausea, dyspepsia, change in bowel habit, constipation, faeces discolored, diarrhea and flatulence.</description>
        <time_frame>Up to Week 8</time_frame>
        <population>Intent to treat (ITT) population which comprised of all participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferrous Bisglycinate Chelate 60 mg 1 Once-daily</title>
            <description>Participants received ferrous bisglycinate chelate, 1 tablet of 60 mg, once-daily after dinner, via oral route for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ferrous Bisglycinate Chelate 60 mg 1 Twice-daily</title>
            <description>Participants received ferrous bisglycinate chelate, 1 tablet each of 60 mg, twice-daily after breakfast and dinner, via oral route for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ferrous Ascorbate 100 mg 1 Once-daily</title>
            <description>Participants received ferrous ascorbate, 1 tablet of 100 mg once-daily after dinner, via oral route for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Percentage of Participants With Gastrointestinal Side Effects During 8 Weeks Treatment With Ferrous Bisglycinate Chelate and Ferrous Ascorbate</title>
          <description>The comparison in percentage of participants with gastrointestinal side effects during 8 week treatment period is reported. Gastrointestinal side effects during 8 weeks treatment included abdominal discomfort, gastritis, nausea, dyspepsia, change in bowel habit, constipation, faeces discolored, diarrhea and flatulence.</description>
          <population>Intent to treat (ITT) population which comprised of all participants who received at least 1 dose of study drug.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="9.9"/>
                    <measurement group_id="O3" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events and non-serious adverse events data was collected from Week 2 (Visit 2) to Week 8 (end of study drug or Visit 5)</time_frame>
      <desc>Serious adverse events and non-serious adverse events are reported for the Intent-to-Treat (ITT) population which comprised of all participants who were randomized and received at least one dose of the study medication</desc>
      <group_list>
        <group group_id="E1">
          <title>Ferrous Bisglycinate Chelate 60 mg 1 Once-daily</title>
          <description>Participants received ferrous bisglycinate chelate, 1 tablet of 60 mg, once-daily after dinner, via oral route for 8 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Ferrous Bisglycinate Chelate 60 mg 1 Twice-daily</title>
          <description>Participants received ferrous bisglycinate chelate, 1 tablet each of 60 mg, twice-daily after breakfast and dinner, via oral route for 8 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Ferrous Ascorbate 100 mg 1 Once-daily</title>
          <description>Participants received ferrous ascorbate, 1 tablet of 100 mg once-daily after dinner, via oral route for 8 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Change in bowel habit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Faeces discolored</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Edema at the site of blood collection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

